75 results about "Right atrial" patented technology

Devices and methods for therapy control based on electromechanical timing involve detecting electrical activation of a patient's heart, and detecting mechanical cardiac activity resulting from the electrical activation. A timing relationship is determined between the electrical activation and the mechanical activity. A therapy is controlled based on the timing relationship. The therapy may improve intraventricular dyssynchrony of the patient's heart, or treat at least one of diastolic and systolic dysfunction and/or dyssynchrony of the patient's heart, for example. Electrical activation may be detected by sensing delivery of an electrical stimulation pulse to the heart or sensing intrinsic depolarization of the patient's heart. Mechanical activity may be detected by sensing heart sounds, a change in one or more of left ventricular impedance, ventricular pressure, right ventricular pressure, left atrial pressure, right atrial pressure, systemic arterial pressure and pulmonary artery pressure.

Techniques are provided for use by a pacemaker or other implantable medical device for estimating optimal atrio-ventricular pacing delays within a patient. The inter-atrial conduction delays (IACDs) are determined based, at least in part, on atrial far-field (AFF) signals sensed using a multi-pole left ventricular (LV) lead, such as an LV lead implanted via the coronary sinus (CS) with a plurality of electrodes. In one example, for intrinsic atrial events, the IACD is equal to the interval from the beginning of a P-wave detected via a right atrial lead and the end (or peak) of an AFF event detected via a left atrial ring electrode of a CS/LV lead. For paced atrial events, the IACD is instead equal to the interval from the A-pulse to the end (or peak) of the AFF event detected via the CS/LV lead. AV/PV pacing delays are then calculated based on the IACD adjusted by an offset.

Techniques are provided for use with an implantable cardiac stimulation device equipped with a multi-pole left ventricular (LV) lead having a proximal electrode implanted near an atrioventricular (AV) groove of the heart of the patient. A left atrial (LA) cardioelectrical event is sensed using the proximal electrode of the LV lead and a corresponding LA cardiomechanical event is also detected, either using an implantable sensor or an external detection system. The electromechanical activation delay between the LA cardioelectrical event and the corresponding LA cardiomechanical event is determined and then pacing delays are set based on the electromechanical activation delay for use in controlling pacing. The pacing delays can include, e.g., AV delays for use with biventricular cardiac resynchronization therapy (CRT) pacing. Other techniques described herein are directed to exploiting right atrial (RA) cardioelectrical events detected via an RA lead for the purposes of setting pacing delays.

A method for monitoring a right atrial pressure (RAP) and a left atrial pressure (LAP) for diagnosis of a heart condition includes positioning a transseptal device with respect to a pulmonary artery to monitor at least one flow characteristic of blood through the pulmonary artery. The transseptal device is configured to generate one or more signals representative of the at least one flow characteristic. A right ventricular end diastolic pressure (RVEDP) and a left ventricular end diastolic pressure (LVEDP) are detected to facilitate monitoring the heart condition.

The present invention provides a pacing device and method that allows for preferential right atrial, at or near the His bundle, and ventricular pacing, either individually or in combination, including tri-ventricular pacing. The pacing device includes a power source and one or more logic circuits allowing for programmable delivery of pacing to any combination of the right atria, the para-Hisian region, and the right and/or the left ventricles. The pacing device allows the user to select which site(s) to pace as well at the appropriate relative timing of pacing impulse delivery to any of these three previously mentioned sites. The device is constructed and arranged to be combined with an atrial sensing/pacing electrode to allow for atrio-ventricular sequential tri-ventricular pacing or variants of such. Also, a defibrillator lead can be incorporated into the device to allow for protection from ventricular arrhythmias and sudden death.

A device for sealing a patent foramen ovale (PFO) in the heart is provided. The device includes a left atrial anchor adapted to be placed in a left atrium of the heart, a right atrial anchor adapted to be placed in a right atrium of the heart, and an elongate member adapted to extend through the passageway and connect the left and right atrial anchors. The right atrial anchor preferably includes a plurality of arms and a cover attached to the arms. The left atrial anchor also includes a plurality of arms and preferably does not include a cover. Preferably, the elongate member has a first end of fixedly connected to the left atrial anchor and a portion, proximal to the first end, releasably connected to the right atrial anchor.

An implantable medical device includes a lead configured to be located proximate to the left ventricle (LV) of the heart, the lead including multiple LV electrodes to sense cardiac activity at multiple LV sensing sites. The a detection module to detect an arrhythmia that represents at least one of a tachycardia and fibrillation based at least in part on the cardiac activity sensed at the multiple LV sensing sites. The ATP therapy module to identify at least one of an ATP configuration or an ATP therapy site based on the cardiac sensed activity at the LV sensing sites, the ATP therapy module to control delivery of antitachycardia pacing (ATP) therapy at the ATP therapy site. The ATP therapy module delivers a stimulus to electrodes at one or more of an LV site, right ventricular (RV) site and right atrial (RA) site, the detection module to sense evoked responses at the LV sensing sites, the ATP therapy module to designate the ATP therapy site to include at least the LV sensing site with a shortest activation time relative to the one or more LV site, RV site and RA site where the stimulus is delivered.

The present invention relates to a kind of bidiscoid antrioventricular valve scaffold with artificial valve. Said bidiscoid scaffold is made up by using shape memory alloy filament through a certain weaving process. It is divided into right atrial discoid face, intermediate waist portion and right ventricular discoid face, the right atrial discoid face and right ventricular discoid face are made into the form of horn mouth, the diameter of said horn mouth is greater than that of intermediate waist portion, the height of the waist portion is half of diameter of waist portion, the diameter of right atrial discoid face is identical to that of right ventricular discoid face, and said valve is formed from wave-shaped valve ring and valve leaf. Besides, said invention also provides the concrete structure of said wave-shaped valve ring and valve leaf.

Left atrial access apparatus and methods are described herein. Different parameters, such as oxygen saturation difference, between the left and right atrial chambers is utilized to guide a needle or catheter into a desired position within the heart. Various sensing elements can be utilized to detect the physiological parameter difference, such as oxygen levels, in the left atrium. The sensor can be carried by the needle, at its tip or along its body, and can measure the physiological parameter levels contained in the blood, fluid, or tissue.

Atrial arrhythmias, a major contributor to cardiovascular morbidity, are believed to be influenced by autonomic nervous system tone. The main purpose of this invention was to highlight new findings that have emerged in the study of effects of autonomic nervous system tone on atrial arrhythmias, and its interaction with class III antiarrhythmic drug effects. This invention evaluates the significance of sympathetic and parasympathetic activation by determining the effects of autonomic nervous system using a vagal and stellar ganglions stimulation, and by using autonomic nervous system neurotransmitters infusion (norepinephrine, acetylcholine). This invention evaluates the autonomic nervous system effects on the atrial effective refractory period duration and dispersion, atrial conduction velocity, atrial wavelength duration, excitable gap duration during a stable circuit (such atrial flutter circuit around an anatomical obstacle), and on the susceptibility of occurrence (initiation, maintenance and termination) of atrial re-entrant arrhythmias in canine. This invention also evaluates whether autonomic nervous system activation effects via a local neurotransimitters infusion into the right atria can alter those of class III antiarrhythmic drug, sotalol, during a sustained right atrial flutter. This invention represents an emergent need to set-up and develop a new class of anti-cholinergic drug therapy for the treatment of atrial arrhythmias and to combine this new anti-cholinergic class to antiarrhythmic drugs. Furthermore, this invention also highlights the importance of a local application of parasympathetic neurotransmitters/blockers and a catheter ablation of the area of right atrium with the highest density of parasympathetic fibers innervation. This may significantly reduce the occurrence of atrial arrhythmias and may preserve the antiarrhythmic effects of any drugs used for the treatment of atrial re-entrant arrhythmias.

A method is provided including making an opening (300) through an atrial septum (302) at a septal site (304) at least 5 mm from a fossa ovalis (330). A first tissue anchor (204) is endovascularly advanced to a left-atrial site (306) on an annulus of a mitral valve (310) or a wall of a left atrium (308) above the annulus. The first tissue anchor (204) is implanted at the left-atrial site (306). A second tissue anchor (24) is endovascularly advanced to a right-atrial site (320) on an annulus of a tricuspid valve (207) or a wall of a right atrium (200) above the annulus. The second tissue (24) anchor is implanted at the right-atrial site (320). The left-atrial site (306) and the right-atrial site (320) are approximated by tensioning a tether (22) that passes through the opening (300) of the atrial septum (302) and connects the first and the second tissue anchors (204, 24). Other embodiments are also described.

The present invention discloses a pulse condition simulation teaching system. The pulse condition simulation teaching system includes a pulse simulation device, a bionic arm, a control unit and a touch display screen; the pulse simulation device includes a right atrial simulated airbag, a right ventricular simulated airbag, a left atrial simulated airbag, a left ventricular simulated airbag, a pulse power mechanism and a one-way valve; the pulse power mechanism is connected with the right atrial simulated airbag; the left ventricular simulated airbag is connected with the bionic arm; the right atrial simulated airbag, the right ventricular simulated airbag, the left atrial simulated airbag, the left ventricular simulated airbag and the bionic arm and the right atrial simulated airbag are connected with one another sequentially through bionic blood vessels; and the bionic arm, the touch display screen, the pulse power mechanism and the one-way valve are connected with the control unit through electric signals. With the pulse condition simulation teaching system of the invention adopted, the pulse condition of a human body can be simulated accurately, a good opportunity for repeated practice and training can be created for learners, and the learners can strengthen the training of finger feeling of pulse diagnosis and master pulse diagnosis techniques of common pulse conditions in the traditional Chinese medicine soon. The pulse condition simulation teaching system is an ideal teaching tool.